Interleukin 28B polymorphism predicts pegylated interferon plus ribavirin treatment outcome in chronic hepatitis C genotype 4†
Article first published online: 3 JAN 2012
Copyright © 2012 American Association for the Study of Liver Diseases
Volume 55, Issue 2, pages 336–342, February 2012
How to Cite
De Nicola, S., Aghemo, A., Grazia Rumi, M., Galmozzi, E., Valenti, L., Soffredini, R., De Francesco, R., Prati, G. M., D'Ambrosio, R., Cheroni, C., Donato, M. F. and Colombo, M. (2012), Interleukin 28B polymorphism predicts pegylated interferon plus ribavirin treatment outcome in chronic hepatitis C genotype 4. Hepatology, 55: 336–342. doi: 10.1002/hep.24683
Potential conflicts of interest: Massimo Colombo, MD, Grant and research support: Merck, Roche, BMS, Gilead Science; Advisory committees: Merck, Roche, Novartis, Bayer, BMS, Gilead Science, Tibotec, Vertex, Achillion; Speaking and teaching: Tibotec, Roche, Novartis, Bayer, BMS, Gilead Science, Vertex. Maria Grazia Rumi, MD, Speaking and Teaching: Roche; Advisory committees: Jannsen; Travel support: Roche. Alessio Aghemo, MD, Advisory committees: Roche; Travel support: BMS, Glaxo Smith-Kline, Bayer. The other authors have no financial disclosures to declare.
- Issue published online: 27 JAN 2012
- Article first published online: 3 JAN 2012
- Accepted manuscript online: 19 SEP 2011 09:08AM EST
- Manuscript Accepted: 3 SEP 2011
- Manuscript Received: 18 JUN 2011
Additional Supporting Information may be found in the online version of this article.
|HEP_24683_sm_SuppTab1.doc||55K||Supplementary Table 1: Epidemiological and clinical characteristics stratified by treatment outcome.|
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.